Prolonged dexamethasone cuts delayed nausea after chemo

August 22, 2012
Prolonged dexamethasone cuts delayed nausea after chemo
Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing a platinum-based drug or an anthracycline, according to research published online Aug. 20 in the Journal of Clinical Oncology.

Joseph A. Roscoe, Ph.D., of the University of Rochester in New York, and colleagues conducted a randomized, double-blind study of the effectiveness of several for the prevention of DN: palonosetron plus dexamethasone followed by prochlorperazine; granisetron plus dexamethasone followed by prochlorperazine; aprepitant plus palonosetron plus dexamethasone followed by aprepitant plus dexamethasone; or palonosetron plus dexamethasone followed by prochlorperazine plus dexamethasone.

The researchers observed no difference between the effects of palonosetron and granisetron on DN when given with dexamethasone on day one followed by prochlorperazine on days two and three. Also, aprepitant was no more effective at reducing DN than prochlorperazine. Some benefit was achieved, however, by adding dexamethasone to prochlorperazine on days two and three.

"Over half of the patients studied experienced DN, and control afforded by all of the antiemetic regimens examined was inadequate. The finding that a second-generation 5-hydroxytryptamine (5-HT RA), palonosetron, showed no greater efficacy in controlling DN than a first-generation 5-HT RA was disappointing," the authors write. "We were similarly disappointed that aprepitant provided no significant benefit over prochlorperazine in controlling DN. More effective regimens for controlling DN are needed and should include the addition of prolonged dexamethasone."

Two authors disclosed to the pharmaceutical industry.

Explore further: Chemo-induced nausea remains big problem, study says

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemo-induced nausea remains big problem, study says

June 2, 2011
A large, phase III study of four commonly used drug regimens to treat chemotherapy-induced nausea concluded that while two regimens were better at managing patients’ queasiness, none were totally effective – prompting ...

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.